Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/
Avtal | $24,000,000 | (Mar 20, 2026)
games2gether | $5,202,945 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)